FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1901-1903 November 5, 2009 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Macdougall, I. C. PubMed Citation

Recombinant human erythropoietin is arguably the most successful therapeutic application of recombinant DNA technology to date. Since the initial reports — which appeared 22 and 23 years ago^1,2 — documented a cure of the anemia of chronic kidney disease with recombinant human erythropoietin, well over a million patients have been treated with it effectively and with minimal drug-related toxicity. Moreover, recombinant human erythropoietin has also been effective in the treatment of patients with cancer, particularly when anemia has been aggravated by chemotherapy.

Although recombinant human erythropoietin merits high marks for efficacy and safety, concerns have arisen about two distinct types . . . [Full Text of this Article]

Source Information

From the Hematology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.